ARAY · Accuray Inc.
AI read · Neutral
The AI's read
The collaboration could bring better imaging to CyberKnife, but the companies are still exploring options. They have announced no product, and future work depends on technical, clinical, commercial, and regulatory review. Accuray's recent results point in different directions. Its loss was 2 cents per share, compared with an expected loss of 10 cents, but sales were $100.9 million against an estimate of $105.3 million. Sales fell 21% from a year earlier, though service sales rose 6%. Its backlog also fell about 27% from a year earlier. The early partnership and mixed results do not show a clear change in Accuray's outlook.